Afrezza — Strategic Intervention

Afrezza — Strategic Intervention Executive Commercialization Context Afrezza, an ultra-rapid-acting inhaled insulin approved by the FDA in June 2014, entered the diabetes marketplace with exceptionally high pre-launch expectations driven by its rapid pharmacokinetics,...

Entresto: When Clinical Strength Was Not Enough

Entresto: When Clinical Strength Was Not Enough Entresto entered the market with significant clinical promise and the potential to reshape heart failure management. Supported by the PARADIGM-HF trial and reinforced through evolving treatment guidelines, the therapy...

Skip to content